IP Library Granted Patent US 7,445,729
Granted Patent B2
US 7,445,729 · App. 11/986,442 · Granted Nov 4, 2008

Stable organic peroxide compositions

Assignee: JR Chem, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,445,729
App. No.
11/986,442
Granted
Nov 4, 2008
Kind
B2
Abstract

Organic peroxide compositions are stabilized against decomposition by the use of antioxidants, resulting in increased shelf life of products made using the compositions.

Claims (21)

1. An emulsion composition comprising:

an aqueous phase; and

an organic phase comprising benzoyl peroxide, an antioxidant and an aryl benzoate ester,

each of the aqueous phase and organic phase being suitable for topical application to the skin of a user.

2. An emulsion composition as in claim 1 wherein the organic phase is a solution.

3. An emulsion composition as in claim 1 wherein the organic phase is a dispersion.

4. An emulsion as in claim 1 wherein the antioxidant is selected from butylated hydroxyl toluene (BHT), butylated hydroxyanisole (BHA), vitamin E acetate, ascorbyl palmitate, tetrahydrocurcuminoids, t-butyl hydroquinone, meta and para cresols, phenolics, and combinations thereof.

5. An emulsion according to claim 1 wherein the aqueous phase comprises at least one component selected from the group consisting of surfactant, humectant, suspending agent, buffer system, and combinations thereof.

6. An emulsion as in claim 1 wherein the organic phase comprises less than 2% antioxidant by weight of the composition, and no more than about 10% benzoyl peroxide by weight of the composition.

7. An emulsion as in claim 1 wherein the organic phase about 5% antioxidant by weight of the composition, and no more than about 20% benzoyl peroxide by weight of the composition.

8. An emulsion as in claim 1 wherein the amount of benzoyl peroxide present exceeds the solubility limit of benzoyl peroxide in the aryl benzoate ester.

9. An emulsion comprising:

an aqueous phase; and

an organic phase comprising a dispersion comprising benzoyl peroxide, an antioxidant and benzyl benzoate in an amount insufficient to completely solubilize the benzoyl peroxide,

each of the aqueous phase and organic phase being suitable for topical application to the skin of a user.

10. A method comprising:

combining benzoyl peroxide, an antioxidant and benzyl benzoate in an amount insufficient to completely solubilize the benzoyl peroxide at room temperature to provide an organic phase;

mixing the dispersion with an aqueous phase to form an emulsion.

11. The method of claim 10 wherein the aqueous phase comprises at least one component selected from the group consisting of surfactant, humectant, suspending agent, buffer system, and combinations thereof.

12. The method of claim 10 wherein the aqueous phase contains glycerin.

13. A method of treating acne comprising applying an emulsion in accordance with claim 9 to the skin of a subject afflicted with acne.

Assignments (17)
RELEASE OF SECURITY INTEREST Recorded Nov 17, 2025
From: TCW ASSET MANAGEMENT COMPANY LLC, AS ADMINISTRATIVE AGENT
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 072928/0385 →
PATENT SECURITY AGREEMENT Recorded Nov 17, 2025
From: OBAGI COSMECEUTICALS LLC
To: LSSF II OFFSHORE INVESTMENTS, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 073625/0459 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
RELEASE OF SECURITY INTEREST Recorded Mar 21, 2025
From: JPMORGAN CHASE BANK, N.A.
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 070592/0979 →
SECURITY INTEREST Recorded Mar 18, 2025
From: OBAGI COSMECEUTICALS LLC
To: TCW ASSET MANAGEMENT COMPANY LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 070546/0595 →
SECURITY INTEREST Recorded Aug 1, 2022
From: OBAGI COSMECEUTICALS LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 060690/0148 →
RELEASE OF SECURITY INTEREST Recorded Jul 29, 2022
From: TCW ASSET MANAGEMENT COMPANY LLC
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 060668/0771 →
RELEASE OF SECURITY INTEREST Recorded Mar 19, 2021
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 055652/0735 →
SECURITY INTEREST Recorded Mar 16, 2021
From: OBAGI COSMECEUTICALS LLC
To: TCW ASSET MANAGEMENT COMPANY LLC, AS COLLATERAL AGENT
Reel/Frame 055613/0083 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 13, 2018
From: OBAGI COSMECEUTICALS LLC
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 047873/0114 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2017
From: OBAGI MEDICAL PRODUCTS, INC.
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 044829/0092 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Nov 14, 2017
From: BARCLAYS BANK PLC
To: OBAGI MEDICAL PRODUCTS, INC.
Reel/Frame 044750/0475 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Nov 14, 2017
From: BANK OF NEW YORK MELLON
To: OBAGI MEDICAL PRODUCTS, INC.
Reel/Frame 044750/0506 →
SECURITY INTEREST Recorded Jul 19, 2017
From: OBAGI MEDICAL PRODUCTS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043041/0718 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2017
From: RAMIREZ, JOSE E.; FARYNIARZ, JOSEPH R.
To: JR CHEM, LLC
Reel/Frame 042130/0336 →
SECURITY INTEREST Recorded Jul 18, 2016
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSH & LOMB PHARMA HOLDINGS CORP.; DENDREON PHARMACEUTICALS, INC.; DOW PHARMACEUTICAL SCIENCES, INC.; MEDICIS PHARMACEUTICAL CORPORATION; OBAGI MEDICAL PRODUCTS, INC.; OMP, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; SOLTA MEDICAL, INC.; VALEANT CANADA LP, BY ITS GENERAL PARTNER VALEANT CANADA GP LIMITED; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT HOLDINGS IRELAND (AS SUCCESSOR TO VALEANT INTERNATIONAL BERMUDA); VALEANT PHARMACEUTICALS NORTH AMERICA LLC; VALEANT PHARMACEUTICALS IRELAND
To: BARCLAYS BANK PLC
Reel/Frame 039380/0385 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2014
From: JR CHEM, LLC
To: OBAGI MEDICAL PRODUCTS, INC.
Reel/Frame 032023/0567 →
Continuity (3)
Continuation 1147652700 · Jun 28, 2006
Provisional Application 6069522300 · Jun 29, 2005
Related Publication 20080067474A1 · Mar 20, 2008